Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial results

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 4, 1996, Pages 35-39

  Kasper, S ^a   Pletan, Y ^b   Solles, A ^b   Tournoux, A ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; MILNACIPARN; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0029851190     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199609004-00005     Document Type: Editorial

References (19)

1. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association.
2. Assie M, Charveron M, Palmier C, Puozzo C, Moret C, Briley M (1992) Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 131:149-155.
3. Caron J, Libersa C, Hazard JR, et al. (1993) Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 3:493-500.
4. Covi L, Lipman R, McNair D, Czerlinski T (1979) Symptomatic volunteers in multicenterdrug trials. Prog Neuropsychopharmacol 3:287-296.
5. De Vane C (1994) Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 97 (suppl 2):13S-23S.
6. Goodnick P (1994) Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 27:307-330.
7. Guy W (ed) (1976) ECDEU Assessment Manual for Psychopharmacology (rev). Rockville, Maryland: National Institute for Mental Health, Psychopharmacology Research Branch.
8. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 12:56-62.
9. Kasper S, Lepine J-P, Mendelewicz J, Montgomery S, Rush A-J (1994) Efficacy, safety and indications for tricyclic and newer antidepressants. Depression 2:127-137.
10. Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V (1966) Clinical efficacy of milnacipran: placebo-controlled trials. Int J Psychopharmacol 11 (suppl 4):29-33.
11. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1966) Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (suppl 4):41-46.
12. Montgomery S, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
13. Moret C, Briley M (1990) Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol 180:351-356.
14. Moret C, Charveron M, Fingerg J, Couzinier J, Briley M (1985) Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219.
15. Neliat G, Bodinier M-C, Panconi E, Briley M (1996) Lack of effect of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the β-adrenoreceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology (in press).
16. Raskin A, Schulterbrandt J, Reatig N, Rice C (1967) Factors of psychopathology in interview, word behaviour and self-report ratings of hospitalised depressions. J Consult Psychol 31:270-278.
17. Spitzer R, Endicott J, Robins E (1978) Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 34: 773-778.
18. Sussman N (1994) The potential benefits of serotonin receptor-specific agents. J Clin Psychiatry 55:45-51.
19. Van Praag H (1984) Studies in the mechanisms of action of serotonin precursors in depression. Psychopharmacol Bull 20:599-602.